229 related articles for article (PubMed ID: 36077268)
1. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
4. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
5. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
6. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
7. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
Worden F; Rajkovic-Hooley O; Reynolds N; Milligan G; Zhang J
Endocrine; 2024 May; 84(2):663-669. PubMed ID: 38102498
[TBL] [Abstract][Full Text] [Related]
9. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
[TBL] [Abstract][Full Text] [Related]
10. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
11. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
12. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
15. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
16. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
18. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
19. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
20. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]